Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 2,402 Shares

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 2,402 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $98,265.82. Following the transaction, the chief executive officer now owns 662,692 shares of the company’s stock, valued at $27,110,729.72. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Twist Bioscience Price Performance

NASDAQ TWST opened at $36.71 on Tuesday. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The firm has a market capitalization of $2.19 billion, a P/E ratio of -10.86 and a beta of 2.15. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The company has a 50-day moving average price of $46.54 and a 200-day moving average price of $45.47.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. During the same quarter in the prior year, the firm earned ($0.75) EPS. The business’s revenue for the quarter was up 24.1% compared to the same quarter last year. Equities research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Barclays set a $58.00 price target on Twist Bioscience and gave the company an “overweight” rating in a report on Monday, February 3rd. TD Cowen restated a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a report on Tuesday, November 26th. Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a report on Tuesday, February 4th. Finally, Wolfe Research started coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and an average price target of $54.40.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Van ECK Associates Corp grew its stake in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after acquiring an additional 267 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Twist Bioscience during the 3rd quarter valued at approximately $34,000. Banque Transatlantique SA bought a new position in shares of Twist Bioscience during the 4th quarter valued at approximately $43,000. GF Fund Management CO. LTD. bought a new position in shares of Twist Bioscience during the 4th quarter valued at approximately $58,000. Finally, US Bancorp DE grew its stake in shares of Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after acquiring an additional 601 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.